ClinicalTrials.gg
Active, not recruitingNCT06230224OLYMPIA-4Updated May 11, 2026

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma

A Phase 3 interventional study of Odronextamab and Ifosfamide in B-Cell Non-Hodgkin Lymphoma (B-NHL), sponsored by Regeneron Pharmaceuticals. Active, not recruiting at 81 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
216
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Lymphoma, B-Cell with a site in Brazil — 6 open to participants now, 11 under way, 8 of them phase 3. Lymphoma, B-Cell · Brazil.

Enrollment
14th of 16
216 · median 460
Started
2024
with 2 others
Phase 3
13 of 19
3 open now
Primary completion
2028-05
later than 7 of 10 live
Registered
14th of 19
by date

Among the 19 studies in Lymphoma, B-Cell with a site in Brazil, this one is the 14th largest by enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2024, is one of 13 in phase 3, reaches primary completion later than 7 of the 10 other live ones, and was the 14th registered.

Lymphoma, B-Cell

885 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

6 of the 19 studies in Lymphoma, B-Cell with a site in Brazil are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 129 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Lymphoma, B-Cell with a site in Brazil, or all of them as a file.
02

Study summary

This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on patients with previously treated aggressive B-cell non-Hodgkin lymphoma whose cancer has stopped responding to treatment (also known as 'refractory') or has returned (also known as 'relapsed'). The aim of the study is to see how safe, tolerable and effective the study drug is when given alone.

The study is looking at several other research questions, including:

  • What side effects may happen from taking the study drug versus Standard of Care (SOC)
  • How much study drug is in the blood at different times
  • Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
  • Comparing the impact from the study drug versus SOC on quality-of-life and ability to complete routine daily activities
03

Conditions studied

  • B-Cell Non-Hodgkin Lymphoma (B-NHL)

Keywords

  • Non-Hodgkin lymphomas (NHLs)
  • Aggressive NHL
  • B-Cell Non-Hodgkin Lymphoma (B-NHL)
  • Odronextamab
  • Anti-CD20 × anti-CD3 bispecific antibody
  • Relapsed/Refractory NHL
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. proven aggressive B-NHL, as described in the protocol. Availability of tumor tissue for submission to central laboratory is required for study enrollment. for histological assessment prior to enrollment is allowed
  2. Have primary or relapse 12 months or less (≤) from initiation of frontline therapy Only patients who received 1 containing an anti-Cluster of Differentiation 20 (CD20) antibody and anthracycline are allowed for enrollment
  3. Have with at least one nodal lesion with longer diameter (LDi) greater than 1.5 cm or at least one extranodal lesion with LDi greater than 1.0 cm, documented by diagnostic imaging (computed tomography [CT] or magnetic resonance imaging [MRI])
  4. Intent to proceed to stem cell transplant (ASCT), as described in the protocol
  5. (ECOG) performance status of 0 to 1
  6. Adequate hematologic and organ function.

Key Exclusion Criteria:

  1. Primary central nervous system (CNS) lymphoma or known involvement by non-primary CNS NHL, as described in the protocol
  2. History of or current relevant CNS pathology, as described in the protocol
  3. A other than NHL unless the participant is adequately and definitively treated and is cancer free for at least 3 years, with the exception of localized prostate cancer, cervical carcinoma in situ, breast cancer in situ, or nonmelanoma skin cancer that was definitively treated
  4. Any other significant active disease or medical condition that could interfere with the conduct of the study or put the participant at significant risk, as described in the protocol
  5. from prior anti-lymphoma treatments and infections, as described in the protocol
  6. Allergy/ to study drug, or .

NOTE: Other protocol defined inclusion / exclusion criteria apply

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
216 participants (actual)

Study arms

  • Experimental
    Odronextamab

    Participants will receive odronextamab monotherapy.

    Drug: Odronextamab

  • Active comparator
    Standard Of Care

    Participants will receive salvage therapy (ifosfamide, carboplatin, etoposide ± rituximab \[ICE ± R\], or dexamethasone, cisplatin, cytarabine ± rituximab \[DHAP ± R\], or gemcitabine, dexamethasone, cisplatin ± rituximab \[GDP ± R\]) and continue with autologous stem cell transplant (ASCT) following a complete response (CR)/partial response (PR).

    Drug: Ifosfamide · Drug: Carboplatin · Drug: Etoposide · Drug: Rituximab · Drug: Dexamethasone · Drug: Cisplatin · Drug: Cytarabine · Drug: Gemcitabine

Interventions

  • Administered by intravenous (IV) infusion

    Also known as: R1979

  • Administered by IV infusion, as part of the ICE ± R salvage therapy

    Also known as: Ifex

  • Administered by IV infusion, as part of the ICE ± R salvage therapy

    Also known as: Paraplatin

  • Administered by IV infusion, as part of the ICE ± R salvage therapy

    Also known as: Etopophos

  • Administered by IV infusion, as part of the ICE ± R, or DHAP ± R, or GDP ± R salvage therapy.

    Also known as: Rituxan

  • Administered by IV, or orally (PO) as part of the DHAP ± R, or GDP ± R salvage therapy.

    Also known as: Decadron

  • Administered by IV infusion, as part of the DHAP ± R or GDP +/-R salvage therapy.

    Also known as: Platinol

  • Administered by IV infusion, as part of the DHAP ± R salvage therapy.

    Also known as: Cytosar-U

  • Administered by IV infusion, as part of the GDP ± R salvage therapy.

    Also known as: Gemzar

06

What researchers measure

Primary outcomes

  1. Event-free survival (EFS) as assessed by independent central review (ICR)

    Time frame: Assessed up to 3 years

Secondary outcomes

  1. Progression free survival (PFS) as assessed by ICR

    Time frame: Assessed up to 3 years

  2. Best overall response (BOR) as assessed by ICR

    Time frame: Assessed up to 6 months

  3. Overall survival (OS)

    Time frame: Assessed up to 3 years

  4. Overall change in physical functioning as measured by scores of the physical function scale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC-QLQ-C30)

    The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a global health status (GHS)/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and global health status / QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden.

    Time frame: Assessed up to 3 years

  5. EFS as assessed by local investigator

    Time frame: Assessed up to 3 years

  6. PFS as assessed by local investigator

    Time frame: Assessed up to 3 years

  7. BOR as assessed by local investigator

    Time frame: Assessed up to 6 months

  8. Complete response (CR) as assessed by ICR

    Time frame: Assessed up to 6 months

  9. CR as assessed by local investigator

    Time frame: Assessed up to 6 months

  10. Duration of response (DOR) assessed by ICR

    Time frame: Assessed up to 3 years

  11. DOR assessed by local investigator

    Time frame: Assessed up to 3 years

  12. Incidence of treatment-emergent adverse events (TEAEs)

    Time frame: Assessed up to 1 year

  13. Severity of TEAEs

    Time frame: Assessed up to 1 year

  14. Odronextamab concentrations in serum

    Time frame: Assessed up to 6 months

  15. Incidence of anti-drug antibodies (ADAs) to odronextamab over the study duration

    Time frame: Assessed up to 6 months

  16. Titers of ADAs to odronextamab over the study duration

    Time frame: Assessed up to 6 months

  17. Incidence of neutralizing antibodies (NAb) to odronextamab over the study duration

    Time frame: Assessed up to 6 months

  18. Measurable residual disease (MRD) status

    Time frame: Assessed up to 6 months

  19. Overall change in patient-reported outcomes (PROs), as measured by scores of the EORTCQLQ- C30

    The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a GHS/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and global health status / QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden.

    Time frame: Assessed up to 3 years

  20. Overall change in PROs, as measured by scores of the Functional Assessment of Cancer Therapy-Lymphoma (FACT-LymS)

    The FACT-Lym lymphoma subscale (LymS) includes 15 items to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from "not at all" (0) to "very much" (4). Higher scores are associated with a worse quality of life.

    Time frame: Assessed up to 3 years

  21. Overall change in PROs, as measured by scores of the EuroQol-5 Dimension-5 Level Scale (EQ-5D-5L)

    The EQ-5D-5L consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: "no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems". The EQ VAS records the participant's self-rated health on a vertical visual analogue scale where the endpoints are labeled "Best imaginable health state" and "Worst imaginable health state".

    Time frame: Assessed up to 3 years

  22. Overall change in score of the Global Population item 5 (GP5) of the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire

    A single item GP5 of the validated FACT-G questionnaire will be used to assess from the participant perspective the overall impact of treatment side-effect. The question item is on a 5-point scale ranging from "not at all" (0) to "very much" (4).

    Time frame: Assessed up to 3 years

07

Study locations

81 sites
08

References and documents

Related links

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2024 (actual). Primary completion is estimated for May 2028, 51 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2023
First posted
Jan 30, 2024
StartActual
Feb 15, 2024
Primary completionEst.
May 29, 2028
CompletionEst.
May 29, 2029
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06230224
Responsible party
Sponsor
First posted
Jan 30, 2024
Start date
Feb 15, 2024
Primary completion
May 29, 2028 (estimated)
Completion
May 29, 2029 (estimated)
Last update
May 11, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Odronextamab

Start the discussion